RTOG-9910

Terminated

Return to Protocol Table

A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer

Principal Investigator

Thomas M. Pisansky

Status

Terminated

Date of Study Termination

May 20, 2022


Disease Site

Genitourinary [GU] Prostate

Phase

III

Developmental Therapeutics

No

Primary Objective

The primary endpoint is to compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.

Patient Population

Histologically confirmed prostate adenocarcinoma within 180 days of randomization

Zubrod performance score 0-1

Prostatic biopsy tumor grading by the Gleason Score classification

Target Accrual

1540

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.